Lipid nanoparticle mediated mRNA delivery in cancer immunotherapy
- PMID: 40738545
- DOI: 10.1016/bs.ai.2025.02.001
Lipid nanoparticle mediated mRNA delivery in cancer immunotherapy
Abstract
Lipid nanoparticles (LNPs) to deliver messenger RNA (mRNA) have emerged as a transformative strategy in cancer immunotherapy. This chapter explores the pivotal role of LNPs in enabling the efficient and targeted delivery of mRNA for cancer treatment, offering an innovative alternative to traditional therapies. LNPs protect mRNA from degradation, ensure its safe passage into the cytoplasm of target cells, and promote the expression of tumor-specific antigens that can activate the immune system against cancer cells. This chapter covers the fundamental properties of lipid nanoparticles, including their composition, structure, and functional modifications, as well as their mechanism of action in mRNA delivery. It also delves into optimizing LNPs to enhance targeting specificity, reduce toxicity, and improve therapeutic efficacy in cancer immunotherapy. Advances in the design of these nanoparticles, including innovations in surface functionalization and their role in overcoming tumor microenvironment barriers, are discussed. The chapter further examines preclinical and clinical applications of LNP-mediated mRNA cancer vaccines and therapies, highlighting recent successes and case studies. In addition, challenges such as ensuring efficient delivery, managing off-target effects, and addressing potential immune reactions are explored. Finally, future perspectives on developing more advanced LNPs and mRNA therapies, including their potential for personalized cancer treatments, are discussed. By providing an in-depth understanding of the current state and future potential of LNP-mediated mRNA delivery, this chapter aims to offer valuable insights into how this technology is shaping the future of cancer immunotherapy.
Keywords: Cancer immunotherapy; Clinical applications; Lipid nanoparticles; Preclinical evidences; Targeting; m RNA.
Copyright © 2025. Published by Elsevier Inc.
Similar articles
-
Lipid Nanoparticles for mRNA Delivery in Cancer Immunotherapy.AAPS J. 2025 Mar 18;27(3):66. doi: 10.1208/s12248-025-01051-8. AAPS J. 2025. PMID: 40102316 Review.
-
Nanoparticles for mRNA-based cancer immunotherapy.Adv Immunol. 2025;166:77-101. doi: 10.1016/bs.ai.2024.10.012. Epub 2025 Feb 4. Adv Immunol. 2025. PMID: 40738546 Review.
-
Lipid nanoparticle-mediated targeted mRNA delivery and its application in cancer therapy.J Mater Chem B. 2025 Aug 20;13(33):10085-10117. doi: 10.1039/d5tb01556a. J Mater Chem B. 2025. PMID: 40757469 Review.
-
Better, Faster, Stronger: Accelerating mRNA-Based Immunotherapies With Nanocarriers.Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024 Nov-Dec;16(6):e2017. doi: 10.1002/wnan.2017. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024. PMID: 39537215 Free PMC article. Review.
-
Immunomodulatory nanoparticles activate cytotoxic T cells for enhancement of the effect of cancer immunotherapy.Nanoscale. 2024 Oct 3;16(38):17699-17722. doi: 10.1039/d4nr01780c. Nanoscale. 2024. PMID: 39257225 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical